

Figure 1

>1662885	CTCTTAGGCT	TTGAAGCATT	TTTGTNTGTG	CTCCCTGATC	TTCATGTCAC
<1662885inh	CTCTTAGGCT	TTGAAGCATT	TTTGTCTGTG	CTCCCTGATC	TTCATGTCAC
>893988	TAGGCT	TTGAAGCATT	TTTGTCTGTG	CTCCCTGATC	TTCAGGTCAC
>901429		GCATT	TTTGTCTGTG	CTCCCTGATC	TTCATGTCAC
Consensus	CTCTTAGGCT	TTGAAGCATT	TTTGTCTGTG	CTCCCTGATC	TTCATGTCAC
>1662885	CACCATGAAG	TTCTTAGCAG	TCCTGGTACT	CTTGGGAGTT	TCCATCTNTC
<1662885inh	CACCATGAAG	TTCTTAGCAG	TCCTGGTACT	CTTGGGAGTT	TCCATCTTTC
>893988	CACCATGAAG	TTCTTAGCAG	TCCTGGTACT	CTTGGGAGTT	TCCATCTTTC
>901429	CACCATGAAG	TTCTTAGCAG	TCCTGGTACT	CTTGGGAGTT	TCCATCTTTC
Consensus	CACCATGAAG	TTCTTAGCAG	TCCTGGTACT	CTTGGGAGTT	TCCATCTTTC
>1662885	TGGTCTCTGC	CCAGAATCCG	ACAACAGCTG	CTNCAGCTGA	CACGNATCCA
<1662885inh	TGGTCTCTGC	CCAGAATCCG	ACAACAGCTG	CTCCAGCTGA	CACGTATCCA
>893988	TGGTCTCTGC	CCAGAATCCG	ACAACAGCTG	CTCCAGCTGA	CACGTATCCA
>901429	TGGTCTCTGC	CCAGAATCCG	ACAACAGCTG	CTCCAGCTGA	CACGTATCCA
Consensus	TGGTCTCTGC	CCAGAATCCG	ACAACAGCTG	CTCCAGCTGA	CACGTATCCA
>1662885	GCTACTGGTC	CTGCTGATGA	TGAAGCCCT	GANGCTGAAA	CCACTGCTGC
<1662885inh	GCTACTGGTC	CTGCTGATGA	TGAAGCCCT	GATGCTGAAA	CCACTGCTGC
>893988	GCTACTGGTC	CTGCTGATGA	TGAAGCCCT	GATGCTGAAA	CCACTGCTGC
>901429	GCTACTGGTC	CTGCTGATGA	TGAAGCCCT	GATGCTGAAA	CCACTGCTGC
Consensus	GCTACTGGTC	CTGCTGATGA	TGAAGCCCT	GATGCTGAAA	CCACTGCTGC
>1662885	T				
<1662885inh	TGCAACCACT	GCGACCACTG	CTGCTCCTAC	CACTGCAACC	ACCGCTGCTT
>893988	TGCAACCACT	GCGACCACTG	CTGCTCCTAC	CACTGCAACC	ACCGCTGCTT
>901429	TGCAACCACT	GCGACCACTG	CTGCTCCTAC	CACTGCAACC	ACCGCTGCTT
Consensus	TGCAACCACT	GCGACCACTG	CTGCTCCTAC	CACTGCAACC	ACCGCTGCTT
<1662885inh	CTACCACTGC	TCGTAAAGAC	ATTCCAGTTT	TACCCAAATG	GGTTGGGGAT
>893988	CTACCACTGC	TCGTAAAGAC	ATTCCAGTTT	TACCCAAATG	GGTTGGGGAT
>901429	NTACCACTGC	TCGTAAAGAC	ATTNCAGTTT	TACCCAAATG	GGTTGGGGAT
>1209814			TTTT	TACCCAAATG	GGTTGGGGAT
Consensus	CTACCACTGC	TCGTAAAGAC	ATTCCAGTTT	TACCCAAATG	GGTTGGGGAT
<1662885inh	CTCCCGAATG	GTAGAGTGTG	TCCCTGAGAT	GGAATCAGCT	TGAGTCTTCT
>893988	CTTCCCGAATG	GTAGAGTGTG	TCCCTGAGAT	GGAATCAGCT	TGAGTCTTCT
>901429	CTCCCGAATG	GTAGAGTGTG	TCCCTGAGAT	GGAATCAGCT	TGAGTCTTCT
>1209814	CTCCCGAATG	GTAGAGTGTG	TCCCTGAGAT	GGAATCAGCT	TGAGTCTTCT
Consensus	CTCCCGAATG	GTAGAGTGTG	TCCCTGAGAT	GGAATCAGCT	TGAGTCTTCT
<1662885inh	GCAATTGGTC	ACAACTATTG	ATGCTCCTG	TGATTTCATC	CAACTACTTA
>1209814	GCAATTGGTC	ACAACTATTG	ATGCTCCTG	TGATTTCATC	CAACTACTTA
Consensus	GCAATTGGTC	ACAACTATTG	ATGCTCCTG	TGATTTCATC	CAACTACTTA
<1662885inh	CCTTGCCTAC	GATATCCCCT	TTATCTCTAA	TCAGTTTATT	TTCTTCAAA
>1209814	CCTTGCCTAC	GATATCCCCT	TTATCTCTAA	TCAGTTTATT	TTCTTCAAA
Consensus	CCTTGCCTAC	GATATCCCCT	TTATCTCTAA	TCAGTTTATT	TTCTTCAAA
<1662885inh	TAAAAAATAA	CTATGAGCAA	CA		
>1209814	TAAAAAATAA	CTATGAGCAA	CAT		
Consensus	TAAAAAATAA	CTATGAGCAA	CAT		

Figure 2

1662885
1662885 inh
893988
901429
1209814






Figure 3A




Lane	Sample	Lane	Sample
1	Normal Breast	7	Prostate Cancer
2	Normal Breast	8	Prostate Cancer
3	Normal Breast	9	Prostate Cancer
4	Normal Prostate	10	LnCap
5	Normal Prostate	11	McF7
6	Normal Prostate		

Figure 3B




Lane	Sample	Lane	Sample
1	Normal Breast	7	Breast Cancer
2	Normal Breast	8	Breast Cancer
3	Normal Breast	9	Breast Cancer
4	Normal Breast	10	Breast Cancer
5	Normal Breast	11	Breast Cancer
6	Normal Breast	12	Breast Cancer

Figure 4



Dot Id	Sample
E9	Salivary gland
F9	Mammary gland
D12	E. coli
G12	Human DNA
H12	Human DNA

FIGURE 5A



Lane	Sample	Lane	Sample
1	Markers (bp)	7	Normal Breast
2	Placental DNA	8	Breast Cancer
3	Normal Breast	9	Breast Cancer
4	Normal Breast	10	Breast Cancer
5	Normal Breast	11	Breast Cancer
6	Normal Breast	12	Breast Cancer

FIGURE 5B




Figure 6




Figure 7






Figure 8

0.5 1.0 2.0 5.0 10.0 20.0 50.0 100.0 200.0 500.0 1000.0




Lane	Sample
1	Biotinylated molecular weight markers
2	Colored molecular weight markers
3	Transfected HEK293 lysate
4	Transfected HEK293 supernatant
5	Negative control lysate
6	Negative control supernatant

Figure 9




Dot blot of 2 ml fractions collected from Nickel chelate column with immunorecognition of material in fractions 20–31.

Figure 10



Lane	Sample
1	Colored molecular weight markers
2	Supernatant prior to chromatography
3	Flow during material loading
4	Material eluting during wash
5	Pooled, dialyzed eluted material

Figure 11




A

B

Panel A - Anti myc/his monoclonal antibody	
Lane	Sample
1	Unrelated protein
2	BS106 expressed in E. Coli
3	Biotinylated markers
4	Colored molecular weight markers
5	Pooled BS106 M/H from 106C1 cells
6	Colored molecular weight markers
7	Biotinylated molecular weight markers


Panel B - Anti BS106 polyclonal antisera	
Lane	Sample
1	Unrelated protein
2	BS106 expressed in E. Coli
3	Biotinylated markers
4	Colored molecular weight markers
5	Pooled BS106 M/H from 106C1 cells
6	Colored molecular weight markers
7	Biotinylated molecular weight markers

Figure 12




Lane	Sample	Lane	Sample
1	Testicle Cancer	6	Prostate
2	Endometrial Cancer	7	Lung
3	Ovarian Cancer	8	Breast Cancer
4	Bladder	9	empty
5	Colon	10	Molecular Weight Markers (kD)

Figure 13






Panel A - Non -Competitive		Panel B - Competitive	
Lane	Sample	Lane	Sample
1	Colored Molecular Marker Weights	1	Colored Molecular Marker Weights
2	Aqueous milk fraction (unreduced)	2	Aqueous milk fraction (unreduced)
3	Aqueous milk fraction (reduced)	3	Aqueous milk fraction (reduced)
4	Fatty milk fraction (unreduced)	4	Fatty milk fraction (unreduced)
5	Fatty milk fraction (reduced)	5	Fatty milk fraction (reduced)

Figure 14



The lanes 1 and 8 in each panel contain colored molecular weight markers (kD).

Figure 15



Conjugates N1-N4 were derived from 5-carboxyfluorescein.
Conjugates M1-M2 were derived from fluorescein-5-maleimide.